A study published in the Journal of Healthcare Risk Management found that anesthesia-related deaths have declined, but complications persist. The research highlights the importance of patient communication, thorough medical history, and preoperative assessments to prevent injuries.
A computer model found that genetic screening for breast cancer risk in conjunction with MRI can reduce cancer deaths and identify a population at an intermediate risk. The study compared two tests to categorize patients by lifetime risk, finding the 7SNP test was most cost-effective for those with an intermediate risk.
A new study published in PLOS ONE suggests that standardized vascular health checks could improve health outcomes and reduce costs in Germany, the UK, France, Denmark, Italy, and Poland. The study used the Archimedes Model to simulate a clinical trial comparing seven health check strategies to current levels of care.
In a post-hoc analysis, elderly patients with type 2 diabetes treated with JANUVIA achieved similar blood sugar reductions as those treated with a sulfonylurea. Notably, patients taking JANUVIA experienced significantly less hypoglycemia, with an incidence of 6.2% compared to 28.2% in patients taking a sulfonylurea.
A post-hoc analysis shows that JANUMET (sitagliptin/metformin) achieved better A1C goal attainment compared to metformin alone, particularly in patients with baseline A1C between 7.5 and 9.0 percent. The study found that nearly half of these patients achieved the target A1C level after 18 weeks on JANUMET.
The Vectra DA algorithm provides a robust molecular monitoring system for RA disease activity. Studies show it can predict progressive joint damage and is robust in patients with common comorbid conditions.
A recent survey conducted by the American College of Endocrinology found that over half of individuals with type 2 diabetes have experienced low blood sugar, often during daily activities. The study highlights the need for increased education on blood sugar management and symptom recognition to prevent serious consequences.
Patients with multiple sclerosis reported significant improvements in quality of life, physical function, and cognitive abilities after one year of TYSABRI treatment. Fatigue and overall well-being also showed notable reductions.
A Phase 2 trial showed that daclizumab combined with interferon beta reduced MS lesion formation by 72 percent compared to interferon beta alone. The treatment also increased a subset of natural killer cells, associated with a decrease in disease activity.
A panel of MS experts provides comprehensive recommendations for selecting and managing patients with MS receiving TYSABRI. The guidelines emphasize the need to weigh treatment benefits against potential risks, including PML and serious adverse events.
Multiple sclerosis patients taking TYSABRI reported significant improvements in both physical function and psychological well-being. After six TYSABRI infusions, patients experienced reduced symptoms and improved quality of life, as measured by the Multiple Sclerosis Impact Scale-29 (MSIS-29) and the 12-item Short Form Scale (SF-12).
Patients who received three infusions of TYSABRI reported significant improvements in general and disease-specific measurements of quality of life (QoL) and cognitive function. Cognitive functioning was assessed by Medical Outcomes Study Cognitive Functioning Scale, with higher scores indicating improved cognition.
Early investigational studies show anti-tumor activity in ZOLINZA (vorinostat) and bortezomib combination for relapsed or refractory multiple myeloma. Clinical trials are underway to further evaluate this combination, offering new hope for advanced multiple myeloma patients.
A new study shows JANUVIA (sitagliptin), a diabetes medicine, effectively lowers blood glucose levels in elderly patients with type 2 diabetes and is not associated with hypoglycemia. The study found that advanced age can contribute to the risk of hypoglycemia, which is why this treatment is beneficial for older patients.